Galenicum launches Dutasteride in the European Market
August 28, 2017
Galenicum launched its new product, Dutasteride, in the European market in July.
Dutasteride is used for treating moderate and severe symptoms of benign prostatic hyperplasia (BPH) in men. The patent for this product expired on July 18 in most European countries.
Galenicum has reached commercial agreements with companies from all over Europe who will sell the product in over 10 European countries. The launch of Dutasteride marks a milestone for Galenicum as the company has been working hard to develop it in recent years.
The launch of this new product highlights and reinforces the company's aim to extend its international presence. This is Galenicum’s second product launch of 2017 following Caspofungin.